News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.